EGFR

Epidermal growth factor receptor; ErbB-1; HER1

The EGFR family of receptor tyrosine kinases (RTK) comprises four distinct receptors: the EGFR (also known as ErbB-1/HER1), ErbB-2 (neu, HER2), ErbB-3 (HER3) and ErbB-4 (HER4). All EGFR family members are characterized by a modular structure consisting of an extracellular ligand-binding domain, a single hydrophobic transmembrane region, and the intracellular part harbouring the highly conserved tyrosine kinase domain. The ErbB family of receptor tyrosine kinases (RTKs) couples binding of extracellular growth factor ligands to intracellular signaling pathways regulating diverse biologic responses, including proliferation, differentiation, cell motility, and survival. Ten growth factors and their ErbB specificities are: EGF, amphiregulin (AR), and TGF bind ErbB-1; betacellulin, and epiregulin bind both ErbB-1 and ErbB-4; the neuregulins (also called heregulins and Neu differentiation factors) NRG-1 and NRG-2 bind ErbB-3 and ErbB-4; and NRG-3 and NRG-4 bind ErbB-4. No known ligand binds ErbB-2. The three best characterized signaling pathways induced through ErbBs are Ras-mitogen-activated protein kinase (Ras-MAPK), phosphatidylinositol 3 kinase-protein kinase B (PI3K-PKB/Akt), and phospholipase C-protein kinase C (PLC-PKC) pathways.

EGFR Inhibitors, Antagonists & Activators

(E)-AG 556

((E)-Tyrphostin AG 556) Cat. No.: HY-101041

(E)-AG 556 is a highly selective **EGFR** inhibitor and also blocks LPS-induced TNF-α production.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

(E)-AG 99

((E)-Tyrphostin 46; (E)-Tyrphostin AG 99) Cat. No.: HY-100962

(E)-AG 99 ((E)-Tyrphostin 46) is a potent **EGFR** inhibitor.



Purity: 99.41%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

(E/Z)-AG490

((E/Z)-Tyrphostin AG490; (E/Z)-Tyrphostin B42) Cat. No.: HY-107459

(E/Z)-AG490 ((E/Z)-Tyrphostin AG490) is a racemic compound of (E)-AG490 and (Z)-AG490 isomers. (E)-AG490 (HY-12000) is a **tyrosine kinase** inhibitor that inhibits **EGFR**, **Stat-3** and **JAK2/3**.



Purity: ≥96.0%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

(E/Z)-CP-724714

Cat. No.: HY-W008914

(E/Z)-CP-724714 is a racemic compound of (E)-CP-724714 and (Z)-CP-724714 isomers. CP-724714 is a potent and selective orally active ErbB2 (HER2) inhibitor.



Purity: >98%
Clinical Data: No Development Reported
Size: 50 mg, 100 mg

(Rac)-JBJ-04-125-02

Cat. No.: HY-135805A

(Rac)-JBJ-04-125-02 is the racemate of JBJ-04-125-02. JBJ-04-125-02 is a potent, mutant-selective, allosteric and orally active **EGFR** inhibitor with an IC_{50} of 0.26 nM for $EGFR^{L858R/T790M}$.



Purity: 98.01%
Clinical Data: No Development Reported
Size: 5 mg

(Rac)-Pyrotinib

((Rac)-SHR-1258) Cat. No.: HY-104065A

(Rac)-Pyrotinib ((Rac)-SHR-1258) is the racemate of Pyrotinib. Pyrotinib is a potent and selective EGFR/HER2 dual inhibitor.



Purity: 98.83%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 25 mg, 50 mg

(S)-Sunvozertinib

((S)-DZD9008) Cat. No.: HY-132842A

(S)-Sunvozertinib ((S)-DZD9008), the S-enantiomer of Sunvozertinib, shows inhibitory activity against **EGFR** exon 20 NPH and ASV insertions, EGFR L858R/T790M mutation and Her2 exon20 YVMA insertion (IC_{50}=51.2 nM, 51.9 nM, 1 nM, and 21.2 nM, respectively).



Purity: 99.14%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

AEE788

(NVP-AEE 788) Cat. No.: HY-10045

AEE788 is an inhibitor of the **EGFR** and **ErbB2** with IC_{50} values of 2 and 6 nM, respectively.



Purity: 98.39%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

AEE788-d5

Cat. No.: HY-10045S

AEE788-d5 is the deuterium labeled AEE788. AEE788 is an inhibitor of the **EGFR** and **ErbB2** with IC_{50} values of 2 and 6 nM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg

Afatinib

(BIBW 2992) Cat. No.: HY-10261

Afatinib (BIBW 2992) is an irreversible **EGFR** family inhibitor with IC_{50}s of 0.5 nM, 0.4 nM, 10 nM and 14 nM for $EGFR^{wt}$, $EGFR^{L858R}$, $EGFR^{L858R/T790M}$ and HER2, respectively.



Purity: 99.93%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg

Afatinib D6

(BIBW 2992 D6) Cat. No.: HY-10261S

Afatinib D6 (BIBW 2992 D6) is deuterium labeled Afatinib. Afatinib (BIBW 2992) is an irreversible EGFR family inhibitor.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Afatinib dimaleate

(BIBW 2992MA2) Cat. No.: HY-10261A

Afatinib dimaleate is an irreversible **EGFR** family inhibitor with IC_{50}s of 0.5 nM, 0.4 nM, 10 nM and 14 nM for $EGFR^{wt}$, $EGFR^{L858R}$, $EGFR^{L858R/T790M}$ and HER2, respectively.



Purity: 99.61%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg

Afatinib impurity 11

Cat. No.: HY-133780

Afatinib impurity 11 is an impurity of Afatinib. Afatinib is an irreversible **EGFR** family inhibitor with IC_{50}s of 0.5 nM, 0.4 nM, 10 nM and 14 nM for $EGFR^{wt}$, $EGFR^{L858R}$, $EGFR^{L858R/T790M}$ and HER2, respectively.



Purity: 99.10%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Afatinib-d4

(BIBW 2992-d4) Cat. No.: HY-10261S1

Afatinib-d4 (BIBW 2992-d4) is the deuterium labeled Afatinib. Afatinib (BIBW 2992) is an irreversible **EGFR** family inhibitor with IC_{50}s of 0.5 nM, 0.4 nM, 10 nM and 14 nM for $EGFR^{wt}$, $EGFR^{L858R}$, $EGFR^{L858R/T790M}$ and HER2, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Afatinib-d6 dimaleate

(BIBW 2992MA2-d6) Cat. No.: HY-10261AS

Afatinib-d6 dimaleate (BIBW 2992MA2-d6) is the deuterium labeled Afatinib dimaleate. Afatinib dimaleate is an irreversible **EGFR** family inhibitor with IC_{50}s of 0.5 nM, 0.4 nM, 10 nM and 14 nM for $EGFR^{wt}$, $EGFR^{L858R}$, $EGFR^{L858R/T790M}$ and HER2, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

AG 555

(Tyrphostin AG 555) Cat. No.: HY-15336

AG 555 (Tyrphostin AG 555), a potent antiretroviral drug, is a potent and selective inhibitor of **EGFR** and blocks **Cdk2** activation.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 100 mg, 250 mg

AG-1478

(Tyrphostin AG-1478; NSC 693255) Cat. No.: HY-13524

AG-1478 (Tyrphostin AG-1478) is a selective **EGFR** tyrosine kinase inhibitor with IC_{50} of 3 nM. AG-1478 has antiviral effects against **HCV** and **encephalomyocarditis virus (EMCV)**.



Purity: 99.22%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

AG-1478 hydrochloride (Tyrphostin AG-1478 hydrochloride; NSC 693255 hydrochloride)

Cat. No.: HY-13524A

AG-1478 hydrochloride (Tyrphostin AG-1478 hydrochloride) is a selective **EGFR** tyrosine kinase inhibitor with IC_{50} of 3 nM. AG-1478 hydrochloride has antiviral effects against **HCV** and **encephalomyocarditis virus (EMCV)**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

AG-494

(Tyrphostin AG 494) Cat. No.: HY-101042

AG-494 (Tyrphostin AG 494) is a potent and selective **EGFR** tyrosine kinase inhibitor (IC_{50}=0.7 μM). AG-494 inhibits the autophosphorylation of EGFR, ErbB2, HER1-2 and PDGF-R with IC_{50}s 1.1, 39, 45 and 6 μM, respectively.



Purity: 99.06%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 25 mg, 50 mg, 100 mg

AG-825

(Tyrphostin AG-825) Cat. No.: HY-15844

AG-825 (Tyrphostin AG-825) is a selective and ATP-competitive **ErbB2** inhibitor which suppresses tyrosine phosphorylation, with an IC_{50} of 0.35 μM. AG-825 displays anti-cancer activity. AG825 significantly accelerates apoptosis of human neutrophils.



Purity: 98.07%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

AG1557

Cat. No.: HY-12806

AG1557 is a specific and ATP competitive inhibitor of epidermal growth factor receptor (**EGFR**) tyrosine kinase, has a **pIC$_{50}$** value of 8.194.



Purity: 99.63%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

AG490

(Tyrphostin AG490; Tyrphostin B42) Cat. No.: HY-12000

AG490 (Tyrphostin AG490) is a tyrosine kinase inhibitor that inhibits **EGFR**, **Stat-3** and **JAK2/3**.



Purity: 99.92%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg

Alflutinib

(Furmonertinib; AST2818) Cat. No.: HY-112870

Alflutinib is a potent inhibitor of **EGFR**. Alflutinib inhibits EGFR active mutations as well as the T790M acquired resistant mutation. Alflutinib has the potential for the research of cancer diseases, especially non-small cell lung cancer (NSCLC).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Alflutinib mesylate

(Furmonertinib mesylate; AST2818 mesylate) Cat. No.: HY-112870A

Alflutinib (Furmonertinib) mesylate is is a potent inhibitor of **EGFR**. Alflutinib (Furmonertinib) mesylate inhibits EGFR active mutations as well as the T790M acquired resistant mutation.



Purity: 98.16%
Clinical Data: Phase 3
Size: 5 mg, 10 mg, 50 mg, 100 mg

Allitinib

(AST-1306; ALS 1306) Cat. No.: HY-15375

Allitinib (AST-1306) is an orally active and irreversible **EGFR** and **ErbB2** inhibitor with **IC$_{50}$**s of 0.5 and 3 nM, respectively. Allitinib also inhibits **ErbB4** with an IC$_{50}$ of 0.8 nM. Allitinib is an anilino-quinazoline compound and has anti-cancer activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Allitinib tosylate

(AST-1306 (TsOH)) Cat. No.: HY-13427

Allitinib tosylate (AST-1306 (TsOH)) is an orally active and irreversible **EGFR** and **ErbB2** inhibitor with **IC$_{50}$**s of 0.5 and 3 nM, respectively. Allitinib tosylate also inhibits **ErbB4** with an IC$_{50}$ of 0.8 nM.



Purity: 99.83%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Almonertinib

(HS-10296) Cat. No.: HY-112823

Almonertinib (HS-10296) is an orally available, irreversible, third-generation **EGFR tyrosine kinase** inhibitor with high selectivity for EGFR-sensitizing and T790M resistance mutations.



Purity: 99.84%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Almonertinib hydrochloride

(HS-10296 hydrochloride) Cat. No.: HY-112823B

Almonertinib (HS-10296) hydrochloride is an orally available, irreversible, third-generation **EGFR tyrosine kinase** inhibitor with high selectivity for EGFR-sensitizing and T790M resistance mutations.



Purity: 98.03%
Clinical Data: Launched
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

ARRY-380 analog

Cat. No.: HY-10531

ARRY-380 analog, an inhibitor of **EGFR (ErbB1)**, is extracted from patent WO2015153959A2, compound 249. ARRY-380 is a potent, selective, ATP-competitive, orally active inhibitor of HER2.



Purity: 96.54%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

ARRY-380 analog-d3

Cat. No.: HY-10531S

ARRY-380 analog-d3 is the deuterium labeled ARRY-380 analog. ARRY-380 analog, an inhibitor of **EGFR (ErbB1)**, is extracted from patent WO2015153959A2, compound 249. ARRY-380 is a potent, selective, ATP-competitive, orally active inhibitor of HER2.



Purity: >98%
Clinical Data: No Development Reported
Size: 25 mg

Tel: 609-228-6898 Fax: 609-228-5909 Email: sales@MedChemExpress.com

ASK120067

Cat. No.: HY-138751

ASK120067 is a potent and orally active inhibitor of **EGFR^{T790M}** (**IC$_{50}$**:0.3 nM) with selectivity over EGFR^{WT} (IC$_{50}$:6.0 nM). ASK120067 is a third-generation EGFR-TKI for the research of non-small cell lung cancer (NSCLC).



Purity: 98.01%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

AST5902 trimesylate

Cat. No.: HY-138627A

AST5902 trimesylate is the principal metabolite of Alflutinib (AST2818) both in vitro and in vivo. AST5902 trimesylate exerts antineoplastic activity. Alflutinib is an **EGFR** inhibitor.



Purity: 99.87%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Astragaloside VI

Cat. No.: HY-N6577

Astragaloside VI could activate **EGFR/ERK** signalling pathway to improve wound healing.



Purity: 99.95%
Clinical Data: No Development Reported
Size: 5 mg

AV-412

(MP412)

Cat. No.: HY-10346

AV-412 (MP412) is an **EGFR** inhibitor with **IC$_{50}$**s of 0.75, 0.5, 0.79, 2.3, 19 nM for EGFR, EGFR^{L858R}, EGFR^{T790M}, EGFR$^{L858R/T790M}$ and ErbB2, respectively.



Purity: 99.17%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

AV-412 free base

(MP-412 free base)

Cat. No.: HY-10346A

AV-412 free base (MP-412 free base) is an **EGFR** inhibitor with **IC$_{50}$**s of 0.75, 0.5, 0.79, 2.3, 19 nM for EGFR, EGFR^{L858R}, EGFR^{T790M}, EGFR$^{L858R/T790M}$ and ErbB2, respectively.



Purity: 98.07%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Avitinib

(Abivertinib; AC0010)

Cat. No.: HY-19816

Avitinib (AC0010) is an irreversible, mutant-selective **EGFR** inhibitor that effectively inhibits EGFR T790M resistance mutations in non-small cell lung cancer (NSCLC). Abivertinib is also a novel **BTK** inhibitor.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Avitinib maleate

(Abivertinib maleate; AC0010 maleate)

Cat. No.: HY-19816A

Avitinib (Abivertinib) maleate is a pyrrolopyrimidine-based irreversible epidermal growth factor receptor (**EGFR**) inhibitor with an **IC$_{50}$** of 7.68 nM.



Purity: 99.17%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

AZ-5104

Cat. No.: HY-B0793

AZ-5104 is an active, demethylated metabolite of AZD 9291. AZ-5104 is an **EGFR** inhibitor with **IC$_{50}$**s of 1, 6, 1, 25 and 7 nM for EGFR$^{L858R/T790M}$, EGFR^{L858R}, EGFR^{L861Q}, EGFR and ErbB4, respectively.



Purity: 99.70%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

AZ7550

Cat. No.: HY-B0794

AZ7550 is an active metabolite of AZD9291 and inhibits the activity of **IGF1R** with an **IC$_{50}$** of 1.6 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

AZ7550 hydrochloride

Cat. No.: HY-B0794A

AZ7550 hydrochloride is an active metabolite of AZD9291 and inhibits the activity of **IGF1R** with an **IC$_{50}$** of 1.6 μM.



Purity: 98.66%
Clinical Data: Phase 1
Size: 5 mg, 10 mg

AZ7550 Mesylate

(AZ7550 trimesylate salt)

Cat. No.: HY-B0794B

AZ7550 Mesylate is an active metabolite of AZD9291 and inhibits the activity of **IGF1R** with an IC_{50} of 1.6 μM.



Purity: 99.34%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg

BAY 2476568

Cat. No.: HY-134877

BAY 2476568 is a potent and selective **EGFR** inhibitor, with IC_{50}s of < 0.2 nM for wild-type EGFR and several mutations (EGFRR ex20insSVD, EGFRR ex20insASV, EGFRR ex20insNPG).



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Befotertinib

(D-0316)

Cat. No.: HY-137433

Befotertinib (D-0316) is the third-generation **EGFR tyrosine kinase** inhibitor. Befotertinib can be used for the research of EGFR T790M-positive non-small cell lung cancer (NSCLC).



Purity: 99.96%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

BGB-102

(JNJ-26483327)

Cat. No.: HY-15732

BGB-102 is a potent multi-kinase inhibitor against **EGFR**, **HER2**, and **HER4** with IC_{50}s of 9.6 nM, 18 nM and 40.3 nM, respectively.



Purity: 97.10%
Clinical Data: Phase 1
Size: 5 mg

BI-4020

Cat. No.: HY-129550

BI-4020 is a fourth-generation, orally active, and non-covalent **EGFR** tyrosine kinase inhibitor.



Purity: 98.82%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

BLU-945

Cat. No.: HY-144680

receptor (**EGFR**). EGFR is a member of the erbB receptor family, which includes transmembrane protein tyrosine kinase receptors. BLU-945 effectively inhibits EGFR with L858R and/or exon 19 deletion mutation, T790M mutation, and C797S mutation.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

BMS-599626

(AC480)

Cat. No.: HY-10251

BMS-599626 (AC480) is a selective and orally bioavailable **HER1** and **HER2** inhibitor, with IC_{50}s of 20 and 30 nM, respectively. BMS-599626 displays ~8-fold less potent to HER4 (IC_{50}=190 nM), >100-fold to VEGFR2, c-Kit, Lck, MEK.



Purity: >98%
Clinical Data: Phase 1
Size: 1 mg, 5 mg

BMS-599626 Hydrochloride

(AC480 Hydrochloride)

Cat. No.: HY-12010

BMS-599626 Hydrochloride (AC480 Hydrochloride) is a selective and orally bioavailable **HER1** and **HER2** inhibitor, with IC_{50}s of 20 and 30 nM, respectively.



Purity: 99.87%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 50 mg, 100 mg

BMS-690514

Cat. No.: HY-10333

BMS-690514 is a potent and orally active inhibitor of **EGFR** and **VEGFR**; has IC_{50}s of 5, 20 and 60 nM for EGFR, HER 2 and HER 4, respectively.



Purity: 99.89%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg

Butein

(2′,3,4,4′-tetrahydroxy Chalcone)

Cat. No.: HY-16558

Butein is a cAMP-specific **PDE** inhibitor with an IC_{50} of 10.4 μM for **PDE4**. Butein is a specific protein tyrosine kinase inhibitor with IC_{50}s of 16 and 65 μM for **EGFR** and **p60**$^{c\text{-}src}$ in HepG2 cells.



Purity: 99.95%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg

Canertinib

(CI-1033; PD-183805) Cat. No.: HY-10367

Canertinib (CI-1033;PD-183805) is a potent and irreversible **EGFR** inhibitor; inhibits cellular **EGFR** and **ErbB2** autophosphorylation with **IC_{50}**s of 7.4 and 9 nM.



Purity: 99.82%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg

Canertinib dihydrochloride

(CI-1033 dihydrochloride; PD-183805 dihydrochloride) Cat. No.: HY-10367A

Canertinib dihydrochloride (CI-1033 dihydrochloride) is a potent and irreversible **EGFR** inhibitor; inhibits cellular **EGFR** and **ErbB2** autophosphorylation with **IC_{50}**s of 7.4 and 9 nM.



Purity: 99.12%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 500 mg

CCT365623 hydrochloride

Cat. No.: HY-124674A

CCT365623 hydrochloride is an orally active **lysyl oxidase (LOX)** inhibitor, with an **IC_{50}** of 0.89 μM. CCT365623 hydrochloride suppresses EGFR (pY1068) and AKT phosphorylation driven by EGF. CCT365623 hydrochloride is extremely well tolerated, and has good pharmacokinetic properties.



Purity: 98.11%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Cetuximab

(C225) Cat. No.: HY-P9905

Cetuximab (C225) is a human IgG1 monoclonal antibody that inhibits epidermal growth factor receptor (**EGFR**), with a **K_d** of 0.201 nM for EGFR by SPR. Cetuximab has potent antitumor activity.

Cetuximab

Purity: 99.70%
Clinical Data: Launched
Size: 1 mg, 5 mg, 25 mg, 50 mg

CGP52411

(DAPH) Cat. No.: HY-103442

CGP52411 (DAPH) is a high selective, potent, orally active and ATP-competitive **EGFR** inhibitor with an **IC_{50}** of 0.3 μM.



Purity: 99.82%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg

CHMFL-EGFR-202

Cat. No.: HY-101522

CHMFL-EGFR-202 is a potent, irreversible inhibitor of **epidermal growth factor receptor (EGFR) mutant kinase**, with **IC_{50}**s of 5.3 nM and 8.3 nM for drug-resistant mutant EGFR T790M and WT EGFR kinases, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Chrysophanol

(Chrysophanic acid) Cat. No.: HY-13595

Chrysophanol (Chrysophanic acid) is a natural anthraquinone, which inhibits EGF-induced phosphorylation of **EGFR** and suppresses activation of **AKT** and **mTOR/p70S6K**.



Purity: 99.73%
Clinical Data: No Development Reported
Size: 50 mg, 100 mg

CL-387785

(EKI-785; WAY-EKI 785) Cat. No.: HY-10325

CL-387785(EKI785; WAY-EKI 785) is an irreversible inhibitor of **EGFR** with **IC_{50}** of 370 pM.



Purity: 98.10%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

CNX-2006

Cat. No.: HY-13897

CNX-2006 is a mutant-selective and irreversible **EGFR** inhibitor with an **IC_{50}** below 20 nM for $EGFR^{T790M}$.



Purity: 99.68%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

CP-724714

Cat. No.: HY-14674

CP-724714 is a potent, selective and orally active **ErbB2 (HER2)** tyrosine kinase inhibitor, with an **IC_{50}** of 10 nM. CP-724714 displays a marked selectivity against EGFR kinase (IC_{50}=6400 nM). CP-724714 potently inhibits ErbB2 receptor autophosphorylation in intact cells.



Purity: 99.33%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

CUDC-101

Cat. No.: HY-10223

CUDC-101 is a potent inhibitor of **HDAC**, **EGFR**, and **HER2** with IC_{50}s of 4.4, 2.4, and 15.7 nM, respectively.



Purity: 99.19%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Cyasterone

Cat. No.: HY-N0211

Cyasterone, a natural **EGFR** inhibitor, mainly isolated from Ajuga decumbens Thunb (Labiatae). Cyasterone manifests anti-proliferation effect by induced **apoptosis** and cell cycle arrests. Cyasterone may serves as a therapeutic anti-tumor agent against human tumors.



Purity: 98.70%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 20 mg

Dacomitinib

(PF-00299804; PF-299804)

Cat. No.: HY-13272

Dacomitinib (PF-00299804) is a specific and irreversible inhibitor of the **ERBB** family of kinases with IC_{50}s of 6 nM, 45.7 nM and 73.7 nM for **EGFR**, **ERBB2**, and **ERBB4**, respectively.



Purity: 99.92%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

Dacomitinib-d10

(PF-00299804-d10; PF-299804-d10)

Cat. No.: HY-13272S3

Dacomitinib-d10 is deuterium labeled Dacomitinib. Dacomitinib (PF-00299804) is a specific and irreversible inhibitor of the ERBB family of kinases with IC50s of 6 nM, 45.7 nM and 73.7 nM for EGFR, ERBB2, and ERBB4, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Dacomitinib-d10 dihydrochloride (PF-00299804-d10 dihydrochloride; PF-299804-d10 dihydrochloride)

Cat. No.: HY-13272S2

Dacomitinib-d10 (PF-00299804-d10) dihydrochloride is the deuterium labeled Dacomitinib dihydrochloride.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Dacomitinib-d3

(PF-00299804-d3; PF-299804-d3)

Cat. No.: HY-13272S

Dacomitinib-d3 (PF-00299804-d3) is the deuterium labeled Dacomitinib. Dacomitinib (PF-00299804) is a specific and irreversible inhibitor of the **ERBB** family of kinases with IC_{50}s of 6 nM, 45.7 nM and 73.7 nM for **EGFR**, **ERBB2**, and **ERBB4**, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Dacomitinib-d5

(PF-00299804-d5; PF-299804-d5)

Cat. No.: HY-13272S1

Dacomitinib-d5 (PF-00299804-d5) is the deuterium labeled Dacomitinib. Dacomitinib (PF-00299804) is a specific and irreversible inhibitor of the **ERBB** family of kinases with IC_{50}s of 6 nM, 45.7 nM and 73.7 nM for **EGFR**, **ERBB2**, and **ERBB4**, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Daphnetin

(7,8-Dihydroxycoumarin)

Cat. No.: HY-N0281

Daphnetin (7,8-dihydroxycoumarin), one coumarin derivative isolated from plants of the Genus Daphne, is a **protein kinase** inhibitor, with IC_{50}s of 7.67 μM, 9.33 μM and 25.01 μM for EGFR, PKA and PKC in vitro, respectively.



Purity: 99.21%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

DBPR112

Cat. No.: HY-128778

DBPR112 is an orally active furanopyrimidine-based **EGFR** inhibitor with IC_{50}s of 15 nM and 48 nM for $EGFR^{WT}$ and $EGFR^{L858R/T790M}$, respectively. DBPR112 can occupy the ATP-binding site. DBPR112 has significant antitumor efficacy.



Purity: 98.07%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Delphinidin 3-glucoside chloride (Delphinidin 3-O-glucoside chloride; Delphinidin 3-O-β-glucoside chloride)

Cat. No.: HY-108052

Delphinidin 3-glucoside chloride (Delphinidin 3-O-glucoside chloride) is an active anthocyanin found in bilberry extract. Delphinidin 3-glucoside chloride induces a pro-apoptotic effect in B cell chronic lymphocytic leukaemia (B CLL).



Purity: 99.83%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Tel: 609-228-6898 Fax: 609-228-5909 Email: sales@MedChemExpress.com

Disitamab vedotin

(RC48) Cat. No.: HY-P9985

Disitamab vedotin (RC48) is an antibody-drug conjugate **(ADC)** comprising a monoclonal antibody against human epidermal growth factor receptor 2 **(HER2)** conjugated via a cleavable linker to the cytotoxic agent Monomethyl auristatin E (MMAE). Disitamab vedotin enhances antitumor immunity.

Disitamab vedotin

Purity: 96.0%
Clinical Data: Launched
Size: 1 mg, 5 mg

Dosimertinib

Cat. No.: HY-142283

Dosimertinib is a highly potent, selective, and orally efficacious deuterated **EGFR** targeting clinical candidate for the treatment of non-small-cell lung cancer.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

DP-C-4

Cat. No.: HY-141481

DP-C-4 is a **Cereblon**-based dual **PROTAC** for simultaneous degradation of **EGFR** and **PARP**.



Purity: 99.72%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

EAI045

Cat. No.: HY-100213

EAI045 is an allosteric and the fourth-generation inhibitor of mutant **EGFR** with IC_{50}s of 1.9, 0.019, 0.19 and 0.002 μM for EGFR, $EGFR^{L858R}$, $EGFR^{T790M}$ and $EGFR^{L858R/T790M}$ at 10 μM ATP, respectively.



Purity: 98.90%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 50 mg, 100 mg

EGFR mutant-IN-1

Cat. No.: HY-125841

EGFR mutant-IN-1, a 5-methylpyrimidopyridone derivative, is a potent and selective $EGFR^{L858R/T790M/C797S}$ mutant inhibitor with an IC_{50} of 27.5 nM, while being a significantly less potent for $EGFR^{WT}$ (IC_{50} >1.0 μM).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

EGFR Protein Tyrosine Kinase Substrate

Cat. No.: HY-P2503

EGFR Protein Tyrosine Kinase Substrate is a EGFR protein tyrosine kinase substrate.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

EGFR-IN-1

Cat. No.: HY-19617

EGFR-IN-1 (compound 24) is an orally active and irreversible **L858R/T790M mutant selective EGFR** inhibitor. EGFR-IN-1 potently inhibits Gefitinib-resistant EGFR L858R, T790M with 100-fold selectivity over wild-type EGFR.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

EGFR-IN-1 hydrochloride

Cat. No.: HY-19617A

EGFR-IN-1 hydrochloride is an orally active and irreversible **L858R/T790M mutant selective EGFR** inhibitor. EGFR-IN-1 hydrochloride potently inhibits Gefitinib-resistant EGFR L858R, T790M with 100-fold selectivity over wild-type EGFR.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

EGFR-IN-1 TFA

Cat. No.: HY-19617B

EGFR-IN-1 TFA is an orally active and irreversible **L858R/T790M mutant selective EGFR** inhibitor. EGFR-IN-1 TFA potently inhibits Gefitinib-resistant EGFR L858R, T790M with 100-fold selectivity over wild-type EGFR.



Purity: 99.05%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

EGFR-IN-11

Cat. No.: HY-130616

EGFR-IN-11 is a fourth-generation **EGFR**-tyrosine kinase inhibitor (**EGFR-TKI**) with an IC_{50} of 18 nM for triple mutant $EGFR^{L858R/T790M/C797S}$.
EGFR-IN-11 significantly suppresses the EGFR phosphorylation, induce the apoptosis, and arrest cell cycle at G0/G1.



Purity: 99.81%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

EGFR-IN-12

Cat. No.: HY-17499

EGFR-IN-12 is a 4,6-disubstituted pyrimidine and is a potent, ATP-competitive, irreversible and highly selective **EGFR** inhibitor with an $IC_{50}$of 21 nM. EGFR-IN-12 also inhibits mutant $EGFR^{L858R}$ and $EGFR^{L861Q}$ with IC_{50}s of 63 nM and 4 nM, respectively.



Purity: 99.49%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg

EGFR-IN-15

Cat. No.: HY-138746

EGFR-IN-15 (compound I-005) is a **EGFR** inhibitor with an IC_{50} of 4 nM. EGFR-IN-15 can be used for oncological diseases research.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

EGFR-IN-16

Cat. No.: HY-137786

EGFR-IN-16 (compound 3) is a potent **EGFR** inhibitor with pIC_{50} of 4.85 and 4.74 for EGFR and HER-2, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

EGFR-IN-17

Cat. No.: HY-115716

EGFR-IN-17 is a potent and selective inhibitor of the **epidermal growth factor receptor** (IC_{50} 0.0002 μM) to overcome C797S-mediated resistance.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

EGFR-IN-18

Cat. No.: HY-139884

EGFR-IN-18 potently inhibits enzymatic activity in L858R/T790M/C797S mutant **EGFR** (4.9 nM), with a significantly lower activity for wild-type **EGFR** (47 nM).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

EGFR-IN-2

Cat. No.: HY-100520

EGFR-IN-2 is a a noncovalent, irreversible, mutant-selective second generation **EGFR** inhibitor.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

EGFR-IN-21

Cat. No.: HY-142678

EGFR-IN-21 is a potent **EGFR** inhibtior with an IC_{50} of 0.38 nM. EGFR-IN-21 has antitumor activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

EGFR-IN-22

Cat. No.: HY-142679

EGFR-IN-22 is a potent **EGFR** inhibitor with IC_{50}s of 4.91 nM and 0.54 nM for **wild type EGFR** and $EGFR^{L858R/T790M/C797S}$, respectively (CN112538072A, compound 243).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

EGFR-IN-23

Cat. No.: HY-142680

EGFR-IN-23 is a potent **EGFR** TKI (tyrosine kinase inhibitor) with an IC_{50} of 8.05 nM for BaF3/EGFR-DEL19/T790M/C797S cell (WO2021244502A1, compound 8).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

EGFR-IN-24

Cat. No.: HY-142512

EGFR-IN-24, a potent EGFR inhibitor, shows inhibition against EGFR(del19/T790M/C797S) and EGFR(L858R/T790M/C797S), respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

EGFR-IN-25

Cat. No.: HY-142517

EGFR-IN-25 is a potent **EGFR** inhibitor with IC_{50}s of 9 nM and 60 nM for BaF3 cells (EGFR DEL19/T790M/C797S) and A431 cells (WT), respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

EGFR-IN-27

Cat. No.: HY-142519

EGFR-IN-27 is a potent EGFR inhibitor with IC_{50}s of <50 nM for EGFR Del, L858R, Del/T790M, L858R/T790M, Del/T790M/C797S, and L858R/T790M/C797S, respectively (WO2021249324A1, compound 511).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

EGFR-IN-28

Cat. No.: HY-142681

EGFR-IN-28 is a potent EGFR inhibitor. EGFR-IN-28 has antitumor activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

EGFR-IN-29

Cat. No.: HY-143729

EGFR-IN-29 is a potent **EGFR** inhibitor, example J-022, extracted from Patent WO2021160087.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

EGFR-IN-30

Cat. No.: HY-144044

EGFR-IN-30 is a potent **EGFR** inhibitor with IC_{50}s of 1-10 nM, <1 nM for EGFR (WT), EGFR (L858R/T790M/C797S), respectively. EGFR-IN-30 has potential for cell proliferative diseases, such as cancer research.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

EGFR-IN-31

Cat. No.: HY-144048

EGFR-IN-31 is a potent inhibitor of **EGFR**. Overexpression and mutation of the epidermal growth factor receptor (EGFR) has been clearly demonstrated to lead to uncontrollable cell growth and is associated with the progression of most cancer diseases, especially NSCLC.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

EGFR-IN-32

Cat. No.: HY-144049

EGFR-IN-32 is a potent inhibitor of **EGFR**. Overexpression and mutation of the epidermal growth factor receptor (EGFR) has been clearly demonstrated to lead to uncontrollable cell growth and is associated with the progression of most cancer diseases, especially NSCLC.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

EGFR-IN-33

Cat. No.: HY-144050

EGFR-IN-33 is a potent inhibitor of **EGFR**. EGFR-IN-33 is an anti-tumor drug with low toxic side effects. EGFR-IN-33 is an acrylamide derivative compound.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

EGFR-IN-34

Cat. No.: HY-144051

EGFR-IN-34 is a potent inhibitor of **EGFR**. EGFR-IN-34 is an anti-tumor drug with low toxic side effects. EGFR-IN-35 is an acrylamide derivative compound.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

EGFR-IN-35

Cat. No.: HY-144052

EGFR-IN-35 is a potent inhibitor of **EGFR**. EGFR-IN-35 is an anti-tumor drug with low toxic side effects. EGFR-IN-35 is an acrylamide derivative compound.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

EGFR-IN-36

Cat. No.: HY-144053

EGFR-IN-36 is a potent **EGFR** inhibitor with IC_{50}s of 19.09 nM, 120.01 nM, 2.35 nM for EGFR (WT), HER2 (WT), HER2 (A775_G776insYVMA), respectively. EGFR-IN-36 has potential for wild and/or mutant EGFR and/or HER2 kinase mediated tumors research.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

EGFR-IN-37

Cat. No.: HY-144054

EGFR-IN-37 is a potent inhibitor of **EGFR**. EGFR-IN-37 is an anti-tumor drug with low toxic side effects. EGFR-IN-39 is an acrylamide derivative compound.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

EGFR-IN-38

Cat. No.: HY-144055

EGFR-IN-38 is a potent inhibitor of **EGFR**. EGFR-IN-38 is an anti-tumor drug with low toxic side effects. EGFR-IN-33 is an acrylamide derivative compound.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

EGFR-IN-39

Cat. No.: HY-144056

EGFR-IN-39 is a potent inhibitor of **EGFR**. EGFR-IN-39 is an anti-tumor drug with low toxic side effects. EGFR-IN-39 is an acrylamide derivative compound.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

EGFR-IN-40

Cat. No.: HY-143901

EGFR-IN-40 (compound 3z) is a potent **BTK**, **EGFR**, and **ITK** inhibitor with IC_{50} values of 1.2 nM, 5.3 nM, and 46.1 nM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

EGFR-IN-42

Cat. No.: HY-145823

EGFR-IN-42 (Compound 17b) is a potent inhibitor of **EGFR** with single-digit nanomolar activity. EGFR-IN-42 connects tamoxifen or endoxifen with the EGFR-inhibitor gefitinib via a covalent linkage. EGFR-IN-42 retains both ER antagonist activity and EGFR inhibition.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

EGFR-IN-43

Cat. No.: HY-145824

EGFR-IN-43 (Compound 17c) is a potent inhibitor of **EGFR** with single-digit nanomolar activity. EGFR-IN-43 connects tamoxifen or endoxifen with the EGFR-inhibitor gefitinib via a covalent linkage. EGFR-IN-43 retains both ER antagonist activity and EGFR inhibition.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

EGFR-IN-44

Cat. No.: HY-145844

EGFR-IN-44 (Compound 6a) is a potent, orally active **EGFR** tyrosine kinase inhibitor with an IC_{50} of 4.11 nM. EGFR-IN-44 induces cell **apoptosis** and shows an oral bioavailability value of 33.57%. EGFR-IN-44 can be studied for non-small-cell lung cancers.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

EGFR-IN-45

Cat. No.: HY-145867

EGFR-IN-45 is a potent epidermal growth factor receptor (**EGFR**) pan inhibitor, with IC_{50}s of 0.4 μM and 1.6 μM for **EGFR** and **CDK2**, respectively. EGFR-IN-45 also inhibit Topo I and Topo II. EGFR-IN-45 arrests cancer cells in the pre-G1 phase and induces **apoptosis**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

EGFR-IN-46

Cat. No.: HY-144794

EGFR-IN-46 is a potent **EGFR** and **FAK** dual inhibitor with IC_{50}s of 20.17 nM, 14.25 nM, respectively. EGFR-IN-46 significantly inhibits the growth of cancer cells. EGFR-IN-46 induces cell **apoptosis**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

EGFR-IN-47

Cat. No.: HY-143337



EGFR-IN-47 is a potent and orally active **EGFR**$^{L858R/T790M/C797S}$ inhibitor with an **IC**$_{50}$ of 0.01 μM. EGFR-IN-47 induces cell cycle attest and cell **apoptosis**. EGFR-IN-47 has the potential for the research of NSCLC.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

EGFR-IN-48

Cat. No.: HY-143445



EGFR-IN-48 is a potent and orally active **EGFR** inhibitor with **IC**$_{50}$s of 0.193 nM, 0.251 nM, 10.4 nM for EGFR$^{d19/TM/CS}$, EGFR$^{LR/TM/CS}$, EGFR^{WT}, respectively.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

EGFR-IN-49

Cat. No.: HY-146782



EGFR-IN-49 is a potent and selective **EGFR** inhibitor with **IC**$_{50}$s of 65.0 nM and 13.6 nM for EGFR^{T790M} and EGFR$^{T790M/L858R}$, respectively. EGFR-IN-49 induces late **apoptosis** in a dose-dependent manner.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

EGFR-IN-5

Cat. No.: HY-111415



EGFR-IN-5 is a **EGFR** inhibitor with **IC**$_{50}$s of 10.4, 1.1, 34, 7.2 nM for EGFR, EGFR^{L858R}, EGFR$^{L858R/T790M}$, and EGFR$^{L858R/T790M/C797S}$, respectively.

Purity: >98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

EGFR-IN-7

Cat. No.: HY-128862



EGFR-IN-7 (compound 34) is a selective and potent **EGFR kinase** inhibitor extracted from patent WO2019015655A1, has **IC**$_{50}$s of 7.92 nM and 0.218 nM for EGFR (WT) and EGFR (mutant C797S/T790M/L858R) respectively, and shows anti-tumor activity.

Purity: 99.76%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg

EGFR-IN-8

Cat. No.: HY-126320



EGFR-IN-8 is a dual **EGFR** and **c-Met** inhibitor, compound 48. EGFR-IN-8 can be a promising candidate for further development to target EGFR TKI-resistant NSCLC.

Purity: 98.31%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

EGFR-IN-9

Cat. No.: HY-18213



EGFR-IN-9 (Compound 8) is a potent **EGFR kinase** inhibitor with **IC**$_{50}$s of 7 nM, 28 nM for the wild type EGFR kinase and double mutant EGFR kinase (L858R/T790M). EGFR-IN-9 has antitumor activity.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

EGFR/BRAF-IN-1

Cat. No.: HY-115933



EGFR/BRAF-IN-1 (compound 21), a 2,3-dihydropyrazino[1,2-a]indole-1,4-dione derivative, is a potent **EGFR/BRAF** inhibitor with an **IC**$_{50}$ of 45 nM for BRAF^{V600E}. EGFR/BRAF-IN-1 inhibits cancer cell proliferation (GI$_{50}$=35 nM). EGFR/BRAF-IN-1 shows good antioxidant activity.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

EGFR/CSC-IN-1

Cat. No.: HY-132883



EGFR/CSC-IN-1 is a potential **EGFR** (**IC**$_{50}$ 10.52 nM) and cancer stem cell (CSC) dual inhibitor for triple-negative breast cancer treatment.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

EGFR/ErbB-2/ErbB-4 inhibitor-2

Cat. No.: HY-112420



EGFR/ErbB-2/ErbB-4 inhibitor-2 (Compound 5) is a **EGFR** and **ErbB** inhibitor with **IC**$_{50}$s of 0.017 μM, 0.08 μM, 1.91 μM.

Purity: 99.69%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

EMI1

Cat. No.: HY-138072

EMI1 is an **EGFR ex19del/T790M/C797S** and **EGFR L858R/T790M/C797S** inhibitor. EMI1 can be used for the research of mutant EGFR-associated, drug-resistant non-small-cell lung cancer (NSCLC).



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

EMI48

Cat. No.: HY-131066

EMI48, the derivative of EMI1, displays greater potency toward mutant **EGFR** than EMI1. EMI48 inhibits **EGFR** triple mutants.



Purity: 99.02%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

EMI56

Cat. No.: HY-131067

EMI56, the derivative of EMI1, displays greater potency toward mutant **EGFR** than EMI1. EMI56 inhibits **EGFR** triple mutants.



Purity: 99.72%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Epertinib

(S-22611)

Cat. No.: HY-107367

Epertinib (S-22611) is a potent, oral, reversible, and selective tyrosine kinase inhibitor of **EGFR**, **HER2** and **HER4**, with IC_{50}s of 1.48 nM, 7.15 nM and 2.49 nM, respectively. Epertinib shows potent antitumor activity.



Purity: ≥98.0%
Clinical Data: Phase 2
Size: 1 mg

Epertinib hydrochloride

(S-22611 hydrochloride)

Cat. No.: HY-107367A

Epertinib hydrochloride (S-22611 hydrochloride) is a potent, orally active, reversible, and selective tyrosine kinase inhibitor of **EGFR**, **HER2** and **HER4**, with IC_{50}s of 1.48 nM, 7.15 nM and 2.49 nM, respectively. Epertinib hydrochloride shows potent antitumor activity.



Purity: 99.76%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Epitinib

(HMPL-813)

Cat. No.: HY-139300

Epitinib is an orally active and selective **epidermal growth factor receptor tyrosine kinase** inhibitor (EGFR-TKI) designed for optimal brain penetration. Epitinib can be used for the research of cancer.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Epitinib succinate

(HMPL-813 succinate)

Cat. No.: HY-139300A

Epitinib succinate is an orally active and selective **epidermal growth factor receptor tyrosine kinase** inhibitor (EGFR-TKI) designed for optimal brain penetration. Epitinib succinate can be used for the research of cancer.



Purity: 99.01%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Erlotinib

(CP-358774; NSC 718781; OSI-774)

Cat. No.: HY-50896

Erlotinib (CP-358774) is a directly acting **EGFR** tyrosine kinase inhibitor, with an IC_{50} of 2 nM for human EGFR. Erlotinib reduces EGFR autophosphorylation in intact tumor cells with an IC_{50} of 20 nM. Erlotinib is used for the treatment of non-small cell lung cancer.



Purity: 99.99%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 500 mg

Erlotinib Hydrochloride (CP-358774 hydrochloride; NSC 718781 hydrochloride; OSI-774 hydrochloride)

Cat. No.: HY-12008

Erlotinib Hydrochloride (CP-358774 Hydrochloride) inhibits purified **EGFR** kinase with an IC_{50} of 2 nM.



Purity: 99.99%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 500 mg

Erlotinib mesylate (CP-358774 mesylate; NSC 718781 mesylate; OSI-774 mesylate)

Cat. No.: HY-12008A

Erlotinib mesylate (CP-358774 mesylate) inhibits purified **EGFR** kinase with an IC_{50} of 2 nM.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Erlotinib-13C6

(CP-358774-13C6; NSC 718781-13C6; OSI-774-13C6) Cat. No.: HY-50896S1

Erlotinib-13C6 (CP-358774-13C6) is a 13C-labeled Erlotinib. Erlotinib is a directly acting EGFR tyrosine kinase inhibitor, with an IC_{50} of 2 nM for human EGFR.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg

Erlotinib-d6

(CP-358774-d6; NSC 718781-d6; OSI-774-d6) Cat. No.: HY-50896S

Erlotinib D6 (CP-358774 D6) is a deuterium labeled Erlotinib (CP-358774). Erlotinib is a directly acting inhibitor EGFR tyrosine kinase inhibitor with an IC_{50} of 2 nM for human EGFR.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg

Erlotinib-d6 hydrochloride (CP-358774-d6 hydrochloride; NSC 718781-d6 hydrochloride; OSI-774-d6 hydrochloride)

Cat. No.: HY-12008S

Erlotinib D6 hydrochloride (CP-358774 D6 hydrochloride) a deuterium labeled Erlotinib Hydrochloride. Erlotinib Hydrochloride inhibits purified EGFR kinase with an IC_{50} of 2 nM.



Purity: 98.13%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Falnidamol

(BIBX 1382) Cat. No.: HY-10322

Falnidamol (BIBX 1382) is an orally active, selective **EGFR tyrosine kinase** inhibitor with an **IC_{50}** of 3 nM. Falnidamol displays > 1000-fold lower potency against ErbB2 (IC_{50}=3.4 μM) and a range of other related tyrosine kinases (IC_{50}>10 μM).



Purity: 96.25%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

FIIN-3

Cat. No.: HY-18603

FIIN-3 is an irreversible inhibitor of **FGFR** with an **IC_{50}** of 13.1, 21, 31.4, and 35.3 nM for FGFR1, FGFR2, FGFR3 and FGFR4, respectively.



Purity: 98.13%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

Gefitinib

(ZD1839) Cat. No.: HY-50895

Gefitinib (ZD1839) is a potent, selective and orally active **EGFR tyrosine kinase** inhibitor with an **IC_{50}** of 33 nM. Gefitinib selectively inhibits EGF-stimulated tumor cell growth (IC_{50} of 54 nM) and that blocks EGF-stimulated **EGFR** autophosphorylation in tumor cells.



Purity: 99.94%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 500 mg, 1 g, 5 g

Gefitinib hydrochloride

(ZD-1839 hydrochloride) Cat. No.: HY-50895A

Gefitinib hydrochloride (ZD1839 hydrochloride) is a potent, selective and orally active **EGFR tyrosine kinase** inhibitor with an **IC_{50}** of 33 nM.



Purity: 99.85%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 500 mg, 1 g, 5 g

Gefitinib N-oxide

Cat. No.: HY-100636

Gefitinib N-oxide is the N-oxide derivative of Gefitinib. Gefitinib is an **EGFR tyrosine kinase** inhibitor, with **IC_{50}** of 2-37 nM in NR6wtEGFR cells.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Gefitinib-based PROTAC 3

Cat. No.: HY-123921

Gefitinib-based PROTAC 3, conjugating an **EGFR** binding element to a **von Hippel-Lindau** ligand via a linker, induces **EGFR** degradation with **DC_{50}**s of 11.7 nM and 22.3 nM in HCC827(exon 19 del) and H3255 (L858R mutantion) cells, respectively.



Purity: 99.98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Gefitinib-d3

Cat. No.: HY-50895S2

Gefitinib-d3 (ZD1839-d3) is the deuterium labeled Gefitinib. Gefitinib (ZD1839) is a potent, selective and orally active **EGFR tyrosine kinase** inhibitor with an **IC_{50}** of 33 nM.



Purity: >98%
Clinical Data:
Size: 1 mg, 10 mg

Gefitinib-d6

(ZD1839-d6) Cat. No.: HY-50895S1

Gefitinib-d6 (ZD1839-d6) is the deuterium labeled Gefitinib. Gefitinib (ZD1839) is a potent, selective and orally active **EGFR tyrosine kinase** inhibitor with an IC_{50} of 33 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Gefitinib-d8

(ZD1839-d8) Cat. No.: HY-50895S

Gefitinib D8 (ZD1839 D8) is a deuterium labeled Gefitinib. Gefitinib is an **EGFR tyrosine kinase** inhibitor, with IC_{50} of 2-37 nM in NR6wtEGFR cells.



Purity: 98.42%
Clinical Data: No Development Reported
Size: 5 mg

Genistein

(NPI 031L) Cat. No.: HY-14596

Genistein, a soy isoflavone, is a multiple **tyrosine kinases** (e.g., **EGFR**) inhibitor which acts as a chemotherapeutic agent against different types of cancer, mainly by altering **apoptosis**, the cell cycle, and angiogenesis and inhibiting metastasis.



Purity: 99.84%
Clinical Data: Phase 4
Size: 10 mM × 1 mL, 100 mg, 500 mg

Genistein-d4

(NPI 031L-d4) Cat. No.: HY-14596S

Genistein-d4 (NPI 031L-d4) is the deuterium labeled Genistein. Genistein, a soy isoflavone, is a multiple **tyrosine kinases** (e.g.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

HER2-IN-5

Cat. No.: HY-143733

HER2-IN-5 is a potent and orally active **HER-2** inhibitor, example 10, extracted from patent WO2021164697.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

HER2-IN-7

Cat. No.: HY-143874

HER2-IN-7 is a potent inhibitor of **HER2**. Deregulation of ErbB family signalling modulates proliferation, invasion, metastasis, angiogenesis, and tumour cell survival.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

HER2-IN-8

Cat. No.: HY-144097

HER2-IN-8 is a **HER-2** inhibitor extracted from patent WO2021179274A1 compound 107. HER2-IN-8 can be used for the research of cancer and inflammation.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

HKI-357

Cat. No.: HY-103443

HKI-357 is an irreversible dual inhibitor of **EGFR** and **ERBB2** with IC_{50}s of 34 nM and 33 nM, respectively. HKI-357 suppresses EGFR autophosphorylation (at Y1068), and AKT and MAPK phosphorylation.



Purity: ≥99.0%
Clinical Data: Phase 1
Size: 10 mg

Icotinib

(BPI-2009) Cat. No.: HY-15164A

Icotinib (BPI-2009) is a potent and specific **EGFR** inhibitor with an IC_{50} of 5 nM; also inhibits mutant $EGFR^{L858R}$, $EGFR^{L858R/T790M}$, $EGFR^{T790M}$ and $EGFR^{L861Q}$.



Purity: 99.95%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Icotinib Hydrochloride

(BPI-2009H) Cat. No.: HY-15164

Icotinib Hydrochloride (BPI-2009) is a potent and specific **EGFR** inhibitor with an IC_{50} of 5 nM; also inhibits mutant $EGFR^{L858R}$, $EGFR^{L858R/T790M}$, $EGFR^{T790M}$ and $EGFR^{L861Q}$.



Purity: 99.84%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

JBJ-02-112-05

Cat. No.: HY-135914

JBJ-02-112-05 is a potent, mutant-selective, allosteric and orally active **EGFR** inhibitor with an IC_{50} of 15 nM for $EGFR^{L858R/T790M}$.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

JBJ-04-125-02

Cat. No.: HY-135805

JBJ-04-125-02 is a potent, mutant-selective, allosteric and orally active **EGFR** inhibitor with an IC_{50} of 0.26 nM for $EGFR^{L858R/T790M}$. JBJ-04-125-02 can inhibit cancer cell proliferation and $EGFR^{L858R/T790M/C797S}$ signaling.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

JCN037

(JGK037)

Cat. No.: HY-136430

JCN037 (JGK037) is non-covalent and BBB-penetrant **EGFR** tyrosine kinase inhibitor, with IC_{50} values of 2.49 nM, 3.95 nM, 4.48 nM for EGFR, p-wtEGFR and pEGFRv, respectively.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

JND3229

Cat. No.: HY-119944

JND3229 is a highly potent and fourth-generation $EGFR^{C797S}$ reversible inhibitor with IC_{50} value of 5.8 nM, and also potently suppressed $EGFR^{L858R/T790M}$ and $EGFR^{WT}$ with IC_{50} values of 30.5 and 6.8 nM.



Purity: 99.38%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

JNJ28871063 hydrochloride

Cat. No.: HY-103441

JNJ28871063 hydrochloride is an orally active, highly selective and ATP competitive **pan-ErbB kinase** inhibitor with IC_{50} values of 22 nM, 38 nM, and 21 nM for ErbB1, ErbB2, and ErbB4, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Khellin

Cat. No.: HY-B1394

Khellin is a furochromone that can be isolated from Ammi visnuga L.. Khellin is an **EGFR** inhibitor with an IC_{50} of 0.15 μM. Khelline has anti-proliferative activity in vitro. Khellin has antispasmodic and coronary vasodilator effects.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Lapatinib

(GW572016; GW2016)

Cat. No.: HY-50898

Lapatinib (GW572016) is a potent inhibitor of the **ErbB-2** and **EGFR** tyrosine kinase domains with IC_{50} values against purified **EGFR** and **ErbB-2** of 10.2 and 9.8 nM, respectively.



Purity: 99.83%
Clinical Data: Launched
Size: 10 mM × 1 mL, 50 mg, 100 mg, 500 mg, 1 g

Lapatinib ditosylate (GW572016 ditosylate monohydrate; GW2016 ditosylate monohydrate)

Cat. No.: HY-50898B

Lapatinib ditosylate monohydrate (GW572016 ditosylate monohydrate) is a potent inhibitor of the **ErbB-2** and **EGFR** tyrosine kinase domains with IC_{50} values against purified **EGFR** and **ErbB-2** of 10.2 and 9.8 nM, respectively.



Purity: 99.78%
Clinical Data: Launched
Size: 10 mM × 1 mL, 50 mg, 100 mg

Lapatinib ditosylate

(GW572016 ditosylate; GW2016 ditosylate)

Cat. No.: HY-50898A

Lapatinib ditosylate (GW572016 ditosylate) is a potent inhibitor of the **ErbB-2** and **EGFR** tyrosine kinase domains with IC_{50} values against purified **EGFR** and **ErbB-2** of 10.2 and 9.8 nM, respectively.



Purity: 99.95%
Clinical Data: Launched
Size: 10 mM × 1 mL, 50 mg, 100 mg, 500 mg, 1 g

Lapatinib-d4-1

(GW572016-d4-1; GW2016-d4-1)

Cat. No.: HY-50898S3

Lapatinib-d4-1 is deuterium labeled Lapatinib. Lapatinib (GW572016) is a potent inhibitor of the ErbB-2 and EGFR tyrosine kinase domains with IC50 values against purified EGFR and ErbB-2 of 10.2 and 9.8 nM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Lapatinib-d5

(GW572016-d5; GW2016-d5) Cat. No.: HY-50898S2

Lapatinib-d5 is deuterium labeled Lapatinib. Lapatinib (GW572016) is a potent inhibitor of the ErbB-2 and EGFR tyrosine kinase domains with IC50 values against purified EGFR and ErbB-2 of 10.2 and 9.8 nM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Lapatinib-d7 dihydrochloride

(GW572016-d7 dihydrochloride; GW2016-d7 dihydrochloride) Cat. No.: HY-50898S1

Lapatinib-d7 (GW572016-d7) dihydrochloride is the deuterium labeled Lapatinib dihydrochloride. Lapatinib (GW572016) dihydrochloride is a potent inhibitor of the **ErbB-2** and **EGFR** tyrosine kinase domains with IC_{50} values against purified **EGFR** and **ErbB-2** of 10.2 and 9.8 nM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Lapatinib-d7 ditosylate

Cat. No.: HY-50898BS

Lapatinib-d7 (GW572016-d7) ditosylate is the deuterium labeled Lapatinib. Lapatinib (GW572016) is a potent inhibitor of the **ErbB-2** and **EGFR** tyrosine kinase domains with IC_{50} values against purified **EGFR** and **ErbB-2** of 10.2 and 9.8 nM, respectively.



Purity: >98%
Clinical Data:
Size: 1 mg, 10 mg

Lavendustin A

(RG-14355) Cat. No.: HY-18963

Lavendustin A (RG-14355), isolated from Streptomyces Griseolavendus, is a potent, specific and ATP-competitive inhibitor of **tyrosine kinase**, with an IC_{50} of 11 ng/mL for EGFR-associated tyrosine kinase.



Purity: ≥95.0%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Lavendustin C

Cat. No.: HY-W013857

Lavendustin C is a potent **Ca^{2+} calmodulin-dependent kinase II (CaMK II)** inhibitor with an IC_{50} of 0.2 μM. Lavendustin C inhibits **EGFR**-associated tyrosine kinase (IC_{50}=0.012 μM) and **$pp60^{c\text{-}src(+)}$** kinase (IC_{50}=0.5 μM) .



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Lazertinib

(YH25448; GNS-1480) Cat. No.: HY-109061

Lazertinib (YH25448) is a potent, highly mutant-selective, blood-brain barrier permeable, orally available and irreversible third-generation **EGFR** tyrosine kinase inhibitor, and can be used in the research of non-small cell lung cancer.



Purity: 99.73%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

LDC0496

Cat. No.: HY-146262

LDC0496 is a potent and selective **EGFR** inhibitor. LDC0496 possesses intense inhibitory potency toward EGFR and Her2 exon20 insertion mutations, as well as selectivity over wild type EGFR and within the kinome.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Lifirafenib

(BGB-283) Cat. No.: HY-18957

Lifirafenib (BGB-283) is a novel and potent **Raf** Kinase and **EGFR** inhibitor with IC_{50} values of 23 and 29 nM for recombinant $BRaf^{V600E}$ and EGFR, respectively.



Purity: 98.02%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Margetuximab

Cat. No.: HY-P99030

Margetuximab (MGAH22) is a chimeric anti-**HER2** monoclonal antibody optimized Fc domain, with an EC_{50} value of 39.33 ng/mL. Margetuximab can be used for researching metastatic HER2-positive breast cancer.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Mavelertinib

(PF-06747775) Cat. No.: HY-12972

Mavelertinib is a selective, orally available and irreversible **EGFR tyrosine kinase inhibitor (EGFR TKI)**, with IC_{50}s of 5, 4, 12 and 3 nM for Del, L858R, and double mutants T790M/L858R and T790M/Del, respectively.



Purity: 99.21%
Clinical Data: Phase 2
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Methyl 2,5-dihydroxycinnamate

Cat. No.: HY-101006

Methyl 2,5-dihydroxycinnamate is an erbstatin analog and a stable, potent inhibitor of EGFR kinase activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Mobocertinib

(TAK-788; AP32788)

Cat. No.: HY-135815

Mobocertinib (TAK-788) is a potent and orally active inhibitor of **EGFR** and **HER2** oncogenic mutants, including exon 20 insertions, with selectivity over WT EGFR. Antitumor activity.



Purity: 99.60%
Clinical Data: Launched
Size: 10 mg, 25 mg, 50 mg, 100 mg, 500 mg

Mobocertinib succinate

(TAK-788 succinate; AP32788 succinate)

Cat. No.: HY-135815A

Mobocertinib succinate (TAK-788 succinate) is a potent and orally active inhibitor of **EGFR** and **HER2** oncogenic mutants, including exon 20 insertions, with selectivity over WT EGFR. Antitumor activity.



Purity: 99.61%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 25 mg, 50 mg, 100 mg, 500 mg

MTX-211

Cat. No.: HY-107364

MTX-211 is a dual inhibitor of **EGFR** and **PI3K**, used for the treatment of cancer and other diseases.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

Mubritinib

(TAK-165)

Cat. No.: HY-13501

Mubritinib (TAK-165) is a potent and selective **EGFR2/HER2** inhibitor with an IC_{50} of 6 nM.



Purity: 99.91%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Mutant EGFR inhibitor

Cat. No.: HY-13984

Mutant EGFR inhibitor is a potent and selective mutant **EGFR** inhibitor extracted from patent WO 2013014448 A1; inhibits $EGFR^{L858R}$, $EGFR^{Exon\ 19\ deletion}$ and $EGFR^{T790M}$.



Purity: 99.10%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Mutated EGFR-IN-1

(Osimertinib analog)

Cat. No.: HY-78869

Mutated EGFR-IN-1 (Osimertinib analog) is a useful intermediate for the inhibitors design for mutated **EGFR**, such as L858R EGFR, Exonl9 deletion activating mutant and T790M resistance mutant.



Purity: 99.36%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Mutated EGFR-IN-2

Cat. No.: HY-128860

Mutated EGFR-IN-2 (compound 91) is a mutant-selective **EGFR** inhibitor extracted from patent WO2017036263A1, which potently inhibits single-mutant EGFR (T790M) and double-mutant EGFR (including L858R/T790M (IC_{50}=1nM) and ex19del/T790M), and can suppress activity...



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Mutated EGFR-IN-3

Cat. No.: HY-130608

Mutated EGFR-IN-3 (compound 3) is a potent, ATP-competitive and highly selective allosteric dibenzodiazepinone inhibitor of the **EGFR(L858R/T790M)** and **EGFR(L858R/T790M/C797S)** mutants with IC_{50} values of 12 nM and 13 nM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Naquotinib

(ASP8273)

Cat. No.: HY-19729

Naquotinib (ASP8273) is an orally available, mutant-selective and irreversible **EGFR** inhibitor; with IC_{50}s of 8-33 nM toward EGFR mutants and 230 nM for EGFR.



Purity: >98%
Clinical Data: Phase 3
Size: 1 mg, 5 mg

Naquotinib mesylate

(ASP8273 (mesylate)) Cat. No.: HY-19803

Naquotinib mesylate (ASP8273 mesylate) is an orally available, mutant-selective and irreversible **EGFR** inhibitor; with IC_{50}s of 8-33 nM toward EGFR mutants and 230 nM for EGFR.



Purity: 98.02%
Clinical Data: Phase 3
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Nazartinib

(EGF816) Cat. No.: HY-12872

Nazartinib (EGF816) is a covalent mutant-selective **EGFR** inhibitor, with K_i and K_{inact} of 31 nM and 0.222 min^{-1} on EGFR(L858R/790M) mutant, respectively.



Purity: 99.48%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Nazartinib mesylate

(EGF816 mesylate) Cat. No.: HY-12872A

Nazartinib mesylate (EGF816 mesylate) is a novel, covalent mutant-selective **EGFR** inhibitor, with K_i and K_{inact} of 31 nM and 0.222 min^{-1} on EGFR(L858R/790M) mutant, respectively.



Purity: >98%
Clinical Data: Phase 2
Size: 1 mg, 5 mg

Neratinib

(HKI-272) Cat. No.: HY-32721

Neratinib (HKI-272) is an orally available, irreversible **tyrosine kinase** inhibitor with IC_{50}s of 59 nM and 92 nM for HER2 and EGFR, respectively.



Purity: 99.59%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 25 mg, 50 mg, 100 mg, 200 mg

Neratinib-d6

Cat. No.: HY-32721S

Neratinib-d6 (HKI-272-d6) is the deuterium labeled Neratinib. Neratinib (HKI-272) is an orally available, irreversible **tyrosine kinase** inhibitor with IC_{50}s of 59 nM and 92 nM for HER2 and EGFR, respectively.



Purity: >98%
Clinical Data:
Size: 1 mg, 10 mg

Nimotuzumab

Cat. No.: HY-P9968

Nimotuzumab is a humanized IgG1 monoclonal antibody targeting **EGFR** with a K_D of 0.21 nM. Nimotuzumab is directed against the extracellular domain of the EGFR blocking the binding to its ligands.

Nimotuzumab

Purity: 96.30%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

NRC-2694

Cat. No.: HY-19909

NRC-2694 is an epidermal growth factor receptor (**EGFR**) antagonist with anti-cancer and anti-proliferative properties.



Purity: 99.71%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 20 mg

NSC 228155

Cat. No.: HY-101084

NSC 228155 is an activator of **EGFR**, binds to the extracellular region of **EGFR** and enhance tyrosine phosphorylation of EGFR.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

NSC114126

Cat. No.: HY-144445

NSC114126 is a potent and orally active inhibitor of EGFR tyrosine kinase (**EGFR-TK**). NSC114126 has strong antiproliferative activities. NSC114126 has the potential for the research of cancer diseases.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

NSC381467

Cat. No.: HY-144444

NSC381467 is a potent and orally active inhibitor of EGFR tyrosine kinase (**EGFR-TK**). NSC381467 has strong antiproliferative activities. NSC381467 has the potential for the research of cancer diseases.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

NSC81111

Cat. No.: HY-144441

NSC81111 is a potent and orally active **EGFR-TK** inhibitor with an IC_{50} of 0.15 nM. NSC81111 has anticaner effects.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

O-Desmethyl gefitinib

Cat. No.: HY-100064

O-Desmethyl gefitinib is an active metabolite of Gefitinib in human plasma. The formation of O-desmethyl gefitinib is dependent on CYP2D6 activity. O-desmethyl gefitinib inhibits **EGFR** with an IC_{50} of 36 nM in subcellular assays.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

O-Desmethyl gefitinib D8

Cat. No.: HY-100064S

O-Desmethyl gefitinib D8 is a deuterium labeled O-Desmethyl gefitinib. O-Desmethyl gefitinib is an active metabolite of Gefitinib in human plasma. The formation of O-desmethyl gefitinib is dependent on CYP2D6 activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

O-Desmethyl gefitinib-d6

Cat. No.: HY-100064S1

O-Desmethyl Gefitinib-d6 is the deuterium labeled O-Desmethyl gefitinib. O-Desmethyl gefitinib is an active metabolite of Gefitinib in human plasma. The formation of O-desmethyl gefitinib is dependent on CYP2D6 activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Olafertinib

Cat. No.: HY-19815

Olafertinib is a third-generation **EGFR** TKI, with GI_{50} values of 5 nM (EGFR L858R/T790M), 10 nM (EGFR del19) and 689 nM (EGFR WT), respectively. Olafertinib has the potential for NSCLC research.



Purity: 99.41%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Olmutinib

(HM61713, BI 1482694)

Cat. No.: HY-19730

Olmutinib (HM61713; BI-1482694) is an orally active and irreversible third **EGFR tyrosine kinase** inhibitor that binds to a cysteine residue near the kinase domain. Olmutinib is used for NSCLC.



Purity: 99.88%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

Oritinib

(SH-1028)

Cat. No.: HY-139920

Oritinib (SH-1028), an irreversible third-generation **EGFR TKI**, overcomes T790M-mediated resistance in non-small cell lung cancer.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Oritinib mesylate

(SH-1028 mesylate)

Cat. No.: HY-139920A

Oritinib (SH-1028) mesylate is a selective, orally active, and pyrimidine-based irreversible inhibitor of **EGFR** with an IC_{50} of 18 nM. Oritinib (SH-1028) mesylate exhibits potent activity against EGFR sensitive and resistant (T790 M) mutations.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Osimertinib

(AZD-9291; Mereletinib)

Cat. No.: HY-15772

Osimertinib (AZD9291) is a covalent, orally active, irreversible, and mutant-selective **EGFR** inhibitor with an apparent IC_{50} of 12 nM against L858R and 1 nM against L858R/T790M, respectively. Osimertinib overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer.



Purity: 99.92%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

Osimertinib dimesylate

(AZD-9291 dimesylate; Mereletinib dimesylate)

Cat. No.: HY-79077

Osimertinib dimesylate (AZD-9291 dimesylate) is an irreversible and mutant selective **EGFR** inhibitor with IC_{50}s of 12 and 1 nM against $EGFR^{L858R}$ and $EGFR^{L858R/T790M}$, respectively.



Purity: 99.96%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

Osimertinib mesylate

(AZD-9291 mesylate; Mereletinib mesylate) Cat. No.: HY-15772A

Osimertinib mesylate (AZD9291 mesylate) is a covalent, orally active, irreversible, and mutant-selective **EGFR** inhibitor with an apparent IC_{50} of 12 nM against L858R and 1 nM against L858R/T790M. Osimertinib overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer.



Purity: 99.94%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

Osimertinib-d6

(AZD-9291-d6; Mereletinib-d6) Cat. No.: HY-15772S

Osimertinib D6 (AZD-9291 D6) is a deuterium labeled osimertinib. Osimertinib is a covalent, orally active, irreversible, and mutant-selective **EGFR** inhibitor with an apparent IC_{50} of 12 nM against L858R and 1 nM against L858R/T790M.



Purity: 99.70%
Clinical Data: No Development Reported
Size: 1 mg

pan-HER-IN-1

Cat. No.: HY-144676

pan-HER-IN-1 (Compound C5) is an irreversible, orally active pan-**HER** inhibitor with IC_{50} values of 0.38, 1.6, 2.2 and 3.5 nM against **EGFR**, **HER4**, $EGFR^{T790M/L858R}$ and **HER2**, respectively. pan-HER-IN-1 induces **apoptosis** and shows antitumor activities.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

pan-HER-IN-2

Cat. No.: HY-144677

pan-HER-IN-2 (Compound C6) is a reversible, orally active pan-**HER** inhibitor with IC_{50} values of 0.72, 2.0, 8.2 and 75.1 nM against **EGFR**, **HER4**, $EGFR^{T790M/L858R}$ and **HER2**, respectively. pan-HER-IN-2 induces **apoptosis** and shows antitumor activities.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Panitumumab

(ABX-EGF) Cat. No.: HY-P99041

Panitumumab (ABX-EGF) is a fully human IgG2 anti-**EGFR** monoclonal antibody. Panitumumab has an anti-tumor activity.

Panitumumab

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PD 174265

Cat. No.: HY-112411

PD 174265 is a potent, cell-permeable, reversible, and selective inhibitor of **EGFR** with an IC_{50} of 450 pM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PD-089828

Cat. No.: HY-112345

PD-089828 is an ATP competitive inhibitor of **FGFR-1**, **PDGFR-β** and **EGFR** (IC_{50}s=0.15, 1.76, and 5.47 μM, respectively) and a noncompetitive inhibitor of **c-Src** tyrosine kinase (IC_{50}=0.18 μM). PD-089828 also inhibits **MAPK** with an IC_{50} of 7.1 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

PD-161570

Cat. No.: HY-100434

PD-161570 is a potent and ATP-competitive **human FGF-1 receptor** inhibitor with an IC_{50} of 39.9 nM and a K_i of 42 nM. PD-161570 also inhibits the **PDGFR**, **EGFR** and **c-Src tyrosine kinases** with IC_{50} values of 310 nM, 240 nM, and 44 nM, respectively.



Purity: 99.04%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

PD153035

(SU-5271; AG1517; ZM 252868) Cat. No.: HY-14346

PD153035 (SU-5271; AG1517; ZM 252868) is a potent **EGFR** inhibitor with K_i and IC_{50} of 6 and 25 pM, respectively.



Purity: 99.24%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

PD153035 Hydrochloride (SU-5271 Hydrochloride; AG1517 Hydrochloride; ZM 252868 Hydrochloride)

Cat. No.: HY-12013

PD153035 Hydrochloride (SU-5271 Hydrochloride) is a potent **EGFR** inhibitor with K_i and IC_{50} of 6 and 25 pM, respectively.



Purity: 99.06%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

PD158780

Cat. No.: HY-18609

PD158780 is a potent **EGFR** family inhibitor with IC_{50}s of 8 pM, 49, 52, 52 nM for EGFR, ErbB2, ErbB3, and ErbB4, respectively.



Purity: 99.52%
Clinical Data: No Development Reported
Size: 10 mg, 50 mg

PD168393

Cat. No.: HY-13896

PD168393 is a potent, selective and cell-permeable inhibitor of **EGFR tyrosine kinase** and **ErbB2**. PD168393 irreversiblely inactivates EGF receptor (IC_{50}=0.7 nM) and is inactive against insulin receptor, PDGFR, FGFR and PKC.



Purity: 98.60%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg

PDZ1i

(113B7)

Cat. No.: HY-124813

PDZ1i is a potent, BBB-penetrated and specific **MDA-9/Syntenin** inhibitor. PDZ1i inhibits crucial GBM (glioblastoma multiforme) signaling involving **FAK** and **EGFRvIII**. PDZ1i reduces **MMP** secretion. PDZ1i can improve survival of brain tumor-bearing mice and reduce tumor invasion.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Pelitinib

(EKB-569; WAY-EKB 569)

Cat. No.: HY-32718

Pelitinib (EKB-569;WAY-EKB 569) is an irreversible inhibitor of **EGFR** with an IC_{50} of 38.5 nM; also slightly inhibits Src, MEK/ERK and ErbB2 with IC_{50}s of 282, 800, and 1255 nM, respectively.



Purity: 98.80%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Pelitinib-d6

Cat. No.: HY-32718S

Pelitinib-d6 (EKB-569-d6) is the deuterium labeled Pelitinib. Pelitinib (EKB-569) is an irreversible inhibitor of **EGFR** with an IC_{50} of 38.5 nM; also slightly inhibits Src, MEK/ERK and ErbB2 with IC_{50}s of 282, 800, and 1255 nM, respectively.



Purity: >98%
Clinical Data:
Size: 1 mg, 10 mg

Pertuzumab

Cat. No.: HY-P9912

Pertuzumab, a humanized IgG1 monoclonal antibody, is a **HER2** dimerization inhibitor for the treatment of metastatic HER2-positive breast cancer.



Purity: 99.10%
Clinical Data: Launched
Size: 1 mg, 5 mg, 25 mg, 50 mg

Pertuzumab (PBS)

Cat. No.: HY-P9912A

Pertuzumab (PBS), a humanized monoclonal antibody, is a **HER2** dimerization inhibitor for the treatment of metastatic HER2-positive breast cancer.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PF-06459988

Cat. No.: HY-19985

PF-06459988 is an irreversible inhibitor of T790M-Containing EGFR Mutants.



Purity: 99.49%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

PF-6274484

Cat. No.: HY-101450

PF-6274484 is a potent **EGFR** inhibitor with K_is of 0.14 nM and 0.18 nM for EGFR-L858R/T790M and WT EGFR, respectively. PF-6274484 inhibits EGFR-L858R/T790M autophosphorylation in H1975 tumor cells and EGFR WT in A549 tumor cells with IC_{50}s of 6.6 and 5.8 nM, respectively.



Purity: 98.41%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

PKI-166

Cat. No.: HY-117155

PKI-166 is a potent, selective and orally bioavailable **EGFR tyrosine kinase** inhibitor, with an IC_{50} of 0.7 nM.



Purity: 98.78%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

PKI-166 hydrochloride

Cat. No.: HY-110328

PKI-166 hydrochloride is a potent, selective and orally active **EGFR tyrosine kinase** inhibitor, with an IC_{50} of 0.7 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

pp60 (v-SRC) Autophosphorylation Site, Phosphorylated

Cat. No.: HY-P2548

pp60 (v-SRC) Autophosphorylation Site, Phosphorylated is the phosphorylated peptide of an EGFR substrate. pp60 (v-SRC) Autophosphorylation Site, Phosphorylated can be used for the screening of EGFR Kinase inhibitors via phosphorylated-substrate quantification.

RRLIEDNE-{pTyr}-TARG

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PROTAC EGFR degrader 2

Cat. No.: HY-144304

PROTAC EGFR degrader 2 is a potent PROTAC **EGFR** degrader. PROTAC EGFR degrader 2 exhibits excellent antiproliferative activity with IC_{50} of 4.0 nM and good EGFR degradation activity with DC50 of 36.51 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PROTAC EGFR degrader 3

Cat. No.: HY-144605

PROTAC EGFR degrader 3 is a potent **PROTAC EGFR** degrader. PROTAC EGFR degrader 3 shows excellent cellular activity against the H1975 and HCC827 cells with high selectively. PROTAC EGFR degrader 3 shows that the lysosome is involved in the degradation process of EGFR mutant degradation.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Pyrotinib

(SHR-1258)

Cat. No.: HY-104065

Pyrotinib (SHR-1258) is a potent and selective **EGFR/HER2** dual inhibitor with IC_{50}s of 13 and 38 nM, respectively.



Purity: 99.61%
Clinical Data: Launched
Size: 1 mg, 5 mg, 10 mg, 25 mg, 50 mg

Pyrotinib dimaleate

(SHR-1258 dimaleate)

Cat. No.: HY-104065B

Pyrotinib dimaleate (SHR-1258 dimaleate) is a potent and selective **EGFR/HER2** dual inhibitor with IC_{50}s of 13 and 38 nM, respectively.



Purity: 99.63%
Clinical Data: Launched
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg

Rezivertinib

(BPI-7711)

Cat. No.: HY-109189

Rezivertinib (BPI-7711) is an orally active, highly selective and irreversible third-generation EGFR tyrosine kinase inhibitor (TKI). Rezivertinib exhibits high potency against the common activation EGFR and the resistance T790M mutations.



Purity: 99.93%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

RG13022

(Tyrphostin RG13022)

Cat. No.: HY-101429

RG13022 is a **tyrosine kinase** inhibitor; inhibits the autophosphorylation reaction of the EGF receptor with an IC_{50} of 4 μM.



Purity: ≥95.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

RG14620

(Tyrphostin RG14620)

Cat. No.: HY-101426

RG14620 is an **EGFR** inhibitor with an IC_{50} of 3 μM.



Purity: 99.85%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Rociletinib

(CO-1686; AVL-301; CNX-419)

Cat. No.: HY-15729

Rociletinib (CO-1686) is an orally delivered kinase inhibitor that specifically targets the mutant forms of **EGFR** including T790M, and the K_i values for EGFRL858R/T790M and EGFRWT are 21.5 nM and 303.3 nM, respectively.



Purity: 99.79%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Rociletinib hydrobromide (CO-1686 hydrobromide; AVL-301 hydrobromide; CNX-419 hydrobromide)

Cat. No.: HY-15729A

Rociletinib hydrobromide (CO-1686 hydrobromide) is an orally delivered kinase inhibitor that specifically targets the mutant forms of **EGFR** including T790M, and the K_i values for EGFRL858R/T790M and EGFRWT are 21.5 nM and 303.3 nM, respectively.



Purity: 98.04%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

RTC-5 (TRC-382)

Cat. No.: HY-123952

RTC-5 (TRC-382) is an optimized phenothiazine with anti-cancer potency. RTC-5 demonstrates efficacy against a xenograft model of an **EGFR** driven cancer, its effects is attributed to concomitant negative regulation of PI3K-AKT and RAS-ERK signaling.



Purity: 98.84%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Sapitinib (AZD-8931)

Cat. No.: HY-13050

Sapitinib (AZD-8931) is a reversible, ATP competitive **EGFR** inhibitor of with IC_{50}s of 4, 3 and 4 nM for EGFR, ErbB2 and ErbB3 in cells, respectively.



Purity: 99.75%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Selatinib

Cat. No.: HY-116437

Selatinib is a reversible and orally active dual **EGFR** and **ErbB2** inhibitor with IC_{50}s of 13 nM and 22.5 nM, respectively. Selatinib has anticancer effects.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Simotinib

Cat. No.: HY-101820

Simotinib is a selective, specific, and orally bioavailable **EGFR** tyrosine kinase inhibitor, with an IC_{50} of 19.9 nM. Antineoplastic activities.



Purity: 99.70%
Clinical Data: Phase 1
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Simotinib hydrochloride

Cat. No.: HY-101820A

Simotinib hydrochloride is a selective, specific, and orally bioavailable **EGFR** tyrosine kinase inhibitor, with an IC_{50} of 19.9 nM. Antineoplastic activities.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

SU5204

Cat. No.: HY-126319

SU5204, a tyrosine kinase inhibitor, has IC_{50}s of 4 and 51.5 μM for **FLK-1 (VEGFR-2)** and **HER2**, respectively.



Purity: 98.89%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Sulforaphene

Cat. No.: HY-N2450

Sulforaphene, isolated from radish seeds, exhibits an ED_{50} against velvetleaf seedlings approximately 2×10^{-4} M. Sulforaphene promotes cancer cells apoptosis and inhibits migration via inhibiting **EGFR**, **p-ERK1/2**, **NFκB** and other signals.



Purity: 99.26%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

Sunvozertinib (DZD9008)

Cat. No.: HY-132842

Sunvozertinib (DZD9008) is a potent **ErbBs** (EGFR, Her2, especially mutant forms) and **BTK** inhibitor.



Purity: 99.71%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

TAK-285

Cat. No.: HY-15196

TAK-285 is a potent, selective, ATP-competitive and orally active **HER2** and **EGFR(HER1)** inhibitor with IC_{50} of 17 nM and 23 nM, respectively. TAK-285 is >10-fold selectivity for **HER1/2** than HER4, and less potent to MEK1/5, c-Met, Aurora B, Lck, CSK etc.



Purity: 98.04%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Tarlox-TKI

Cat. No.: HY-43533

Tarlox-TKI, the active metabolite of Tarloxotinib, is an irreversible pan-**ErbB** TKI (Tarlox-TKI).



Purity: 96.93%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg

Tarloxotinib bromide

(TH-4000) Cat. No.: HY-17632

Tarloxotinib bromide (TH-4000) is an irreversible **EGFR/HER2** inhibitor.



Purity: 98.97%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

TAS0728

Cat. No.: HY-111553

TAS0728 is a potent, selective, orally active, irreversible and covalent-binding **HER2** inhibitor, binds to HER2 at C805, inhibits its kinase activity, with an IC_{50} of 13 nM.



Purity: 99.15%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

TAS6417

(CLN-081) Cat. No.: HY-112299

TAS6417 (CLN-081) is a highly effective, orally active and **pan-mutation-selective EGFR** tyrosine kinase inhibitor with a unique scaffold fitting into the ATP-binding site of the EGFR hinge region, with IC_{50} values ranging from 1.1-8.0 nM.



Purity: 98.77%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Tephrosin

(Deguelinol I; Hydroxydeguelin) Cat. No.: HY-N1166

Tephrosin is a natural rotenoid which has potent antitumor activities. Tephrosin induces degradation of of **EGFR** and **ErbB2** by inducing internalization of the receptors.



Purity: ≥97.0%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Tesevatinib

(XL-647; EXEL-7647; KD-019) Cat. No.: HY-13314

Tesevatinib (XL-647; EXEL-7647; KD-019) is an orally available, multi-target tyrosine kinase inhibitor; inhibits **EGFR**, **ErbB2**, **KDR**, **Flt4** and **EphB4** kinase with IC_{50}s of 0.3, 16, 1.5, 8.7, and 1.4 nM.



Purity: 99.21%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg

Tezatabep matraxetan

Cat. No.: HY-139565

Tezatabep matraxetan is a radiolabeled polypeptide used for diagnosis and research of cancer characterized by overexpression of **HER2**.

Tezatabep matraxetan

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Theliatinib

(Xiliertinib; HMPL-309) Cat. No.: HY-104066

Theliatinib (Xiliertinib) is a potent, ATP-competitive, orally active and highly selective **EGFR** inhibitor with a K_i of 0.05 nM and an IC_{50} of 3 nM. Theliatinib has an IC_{50} of 22 nM for **EGFR T790M/L858R mutant**.



Purity: 99.88%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Trastuzumab

(Anti-Human HER2, Humanized Antibody) Cat. No.: HY-P9907

Trastuzumab is a humanized IgG1 monoclonal antibody for patients with invasive breast cancers that overexpress HER2. Trastuzumab has the potential for HER2 Positive Metastatic Breast Cancer and HER2 Positive Gastric Cancer research.

Trastuzumab

Purity: 99.80%
Clinical Data: Launched
Size: 1 mg, 5 mg, 25 mg, 50 mg

Trastuzumab deruxtecan

(DS-8201; DS-8201a) Cat. No.: HY-138298A

Trastuzumab deruxtecan (DS-8201a) is an anti-**human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate (ADC)**.

Trastuzumab deruxtecan

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Trastuzumab deruxtecan (solution)

(DS-8201 (solution); DS-8201a (solution)) Cat. No.: HY-138298

Trastuzumab deruxtecan (DS-8201a) (solution) is an anti-**human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate (ADC)**.

Trastuzumab deruxtecan

Purity: 99.40%
Clinical Data: Launched
Size: 5 mg (10 mg × mL * 500 μL in Aqμeoμs solμtion)

Trastuzumab emtansine

(Ado-Trastuzumab emtansine; PRO132365; T-DM 1) Cat. No.: HY-P9921

Trastuzumab emtansine (Ado-Trastuzumab emtansine) is an antibody-drug conjugate (ADC) that incorporates the HER2-targeted antitumor properties of trastuzumab with the cytotoxic activity of the microtubule-inhibitory agent DM1 (derivative of maytansine).

Trastuzumab emtansine

Purity: ≥99.40%
Clinical Data: Launched
Size: 1 mg, 5 mg, 10 mg

Tucatinib

(Irbinitinib; ARRY-380; ONT-380) Cat. No.: HY-16069

Tucatinib (Irbinitinib) is a potent, orally active and selective **HER2** inhibitor with an **IC_{50}** of 8 nM.



Purity: 99.82%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 500 mg

Tucatinib hemiethanolate (Irbinitinib hemiethanolate; ARRY-380 hemiethanolate; ONT-380 hemiethanolate)

Cat. No.: HY-16069A

Tucatinib (Irbinitinib) hemiethanolate is a potent, orally active and selective **HER2** inhibitor with an **IC_{50}** of 8 nM.



Purity: 99.45%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Tuxobertinib

(BDTX-189) Cat. No.: HY-136789

Tuxobertinib (BDTX-189) is a potent, orally active and selective inhibitor of allosteric **EGFR** and **HER2** oncogenic mutations, including EGFR/HER2 exon 20 insertion mutants. Tuxobertinib shows **K_D**s of 0.2, 0.76, 13 and 1.2 nM for EGFR, HER2, BLK and RIPK2, reapectively. Anticancer activity.



Purity: 99.94%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

TX1-85-1

Cat. No.: HY-100848

TX1-85-1 is an irreversible **Her3 (ErbB3)** inhibitor with an **IC_{50}** of 23 nM. TX1-85-1 is also the first selective **Her3 ligand**, which forms a covalent bond with Cys721 located in the ATP-binding site of Her3.



Purity: 98.07%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Tyrphostin 23

(Tyrphostin A23; RG-50810; AG 18) Cat. No.: HY-15644

Tyrphostin 23 (Tyrphostin A23) is an **EGFR** inhibitor with an **IC_{50}** and **K_i**of 35 and 11 μM, respectively.



Purity: 98.80%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg

Tyrphostin 25

(AG82; Tyrphostin A 25; Tyrphostin AG 82; RG-50875) Cat. No.: HY-101958

Tyrphostin 25 (AG82) is a specific inhibitor of the **EGFR tyrosine kinase**. Tyrphostin 25 is also a **GPR35** agonist with an **IC_{50}** of 0.94 μM and an **EC_{50}** of 5.3 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Tyrphostin 8

Cat. No.: HY-W174279

Tyrphostin 8 is a **tyrosine kinase**, with an **IC_{50}** of 560 μM for **EGFR kinase**. Tyrphostin 8 is also a **GTPase** inhibitor. Tyrphostin 8 can inhibit the protein **serine/threonine phosphatase calcineurin** (**IC_{50}**=21 μM).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Tyrphostin AG 112

Cat. No.: HY-112474

Tyrphostin AG 112 is an **EGFR phosphorylation** inhibitor.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Tyrphostin AG 528

(Tyrphostin B66; AG 528) Cat. No.: HY-100499

Tyrphostin AG 528 is an inhibitor of **EGFR** and **ErbB2** with IC_{50}s of 4.9 and 2.1 μM, respectively. Tyrphostin AG 528 (Tyrphostin B66) is a protein tyrosine kinase inhibitor, with IC_{50}s of 4.9 μM for **epidermal growth factor receptors (EGFR)** and 2.1 μM for **ErbB2**.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Tyrphostin AG 879

(AG 879) Cat. No.: HY-20878

Tyrphostin AG 879 (AG 879) is a tyrosine kinase inhibitor that inhibits **TrKA** phosphorylation (IC_{50} of 10 μM), but not TrKB and TrKC.



Purity: 99.54%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Tyrphostin AG30

(AG30) Cat. No.: HY-118532

Tyrphostin AG30 (AG30) is a potent and selective **EGFR tyrosine kinase** inhibitor. Tyrphostin AG30 (AG30) selectively inhibits self renewal induction by c-ErbB, and is able to inhibit activation of STAT5 by c-ErbB in primary erythroblasts.



Purity: 98.60%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Varlitinib

(ASLAN001; ARRY-334543) Cat. No.: HY-10530

Varlitinib (ASLAN001) is a potent, reversible, small molecule pan-**EGFR** inhibitor with IC_{50}s of 7, 2, 4 nM for HER1, HER2 and HER4, respectively.



Purity: 96.66%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

VEGFR-IN-1

Cat. No.: HY-101219

VEGFR-IN-1 (compound 3) is a potent angiogenesis inhibitor with IC_{50}s of 0.02, 0.18, 0.24 7.3, and 7 μM for **KDR**, **Flt-1**, c-Kit, EGF-R, and c-Src, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

WHI-P154

Cat. No.: HY-13895

WHI-P154 is a potent **EGFR** inhibitor, and also modestly blocks **JAK3**, with IC_{50}s of 4 nM and 1.8 μM, respectively.



Purity: 98.92%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg

WHI-P180

(Janex 3) Cat. No.: HY-15769

WHI-P180 (Janex 3) is a multi-kinase inhibitor; inhibits **RET**, **KDR** and **EGFR** with IC_{50}s of 5 nM, 66 nM and 4 μM, respectively.



Purity: 99.76%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg

WHI-P180 hydrochloride

(Janex 3 hydrochloride;) Cat. No.: HY-15769A

WHI-P180 (Janex 3) is a multi-kinase inhibitor; inhibits **RET**, **KDR** and **EGFR** with IC_{50}s of 5 nM, 66 nM and 4 μM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

WZ-3146

Cat. No.: HY-12001

WZ3146 is a mutant selective **EGFR** inhibitor with IC_{50}s of 2, 2, 5, 14 and 66 nM for $EGFR^{L858R}$, $EGFR^{L858R/T790M}$, $EGFR^{E746\_A750}$, $EGFR^{E746\_A750/T790M}$ and EGFR, respectively.



Purity: 99.63%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

WZ4002

Cat. No.: HY-12026

WZ4002 is a mutant selective **EGFR** inhibitor with IC_{50}s of 2, 8, 3 and 2 nM for $EGFR^{L858R}$, $EGFR^{L858R/T790M}$, $EGFR^{E746\_A750}$ and $EGFR^{E746\_A750/T790M}$, respectively.



Purity: 99.69%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

WZ8040

Cat. No.: HY-12029

WZ8040 is an irreversible mutated **EGFR T790M** inhibitor and inhibits **EGFR phosphorylation**. WZ8040 displays 100-fold greater activity against the mutated EGFR than the normal.



Purity: 99.22%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

ZD-4190

Cat. No.: HY-U00002

ZD-4190 is a potent, orally available inhibitor of the vascular endothelial cell growth factor receptor 2 (**VEGFR2**) and of epidermal growth factor receptor (**EGFR**) signalling, used for the treatment of cancer.



Purity: 99.20%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg

Zorifertinib

(AZD3759)

Cat. No.: HY-18750

Zorifertinib (AZD3759) is a potent, orally active, central nervous system-penetrant, **EGFR** inhibitor. At K_m ATP concentrations, the **IC_{50}**s are 0.3, 0.2, and 0.2 nM for $EGFR^{wt}$, $EGFR^{L858R}$, and $EGFR^{exon\ 19Del}$, respectively.



Purity: 99.76%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

β-Hydroxyisovalerylshikonin

Cat. No.: HY-N4201

Beta-hydroxyisovalerylshikonin is a natural product isolated from Lithospermium radix, acts as a potent inhibitor of **protein tyrosine kinases (PTK)**, with **IC_{50}**s of 0.7μM and 1μM for EGFR and v-Src receptor, respectively.



Purity: 99.83%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg